Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et...
Transcript of Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et...
![Page 1: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/1.jpg)
Institut de Cardiologie de la Pitié-Salpêtriè[email protected]
www.action-coeur.org
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom ?
![Page 2: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/2.jpg)
Patients with CAD and AF have Worse Outcomes
than Patients with CAD without AF
6.92
3.42
1.49
0
1
2
3
4
5
6
7
8
Death / MI / stroke CV death Bleeding
Pa
tie
nts
(%
)
AF
No AF
p<0.0001
p<0.0001
p<0.0001
REACH registry*, outcomes at 1 year
37,724 patients with CAD: 12.5% prevalence of AF
Goto S et al., Am Heart J 2008;156:855-863.
*REduction of Atherothrombosis for Continued Health (REACH) Registry: International, prospective cohort of 68,236 stable outpatients with established atherothrombosis or >3 atherothrombotic risk factors. CV, cardiovascular
4.1
1.69
0.81
![Page 3: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/3.jpg)
Crude event rates in AF after MI or PCI
Circulation. 2014;129:1577-1585
![Page 4: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/4.jpg)
Lancet. 2009 Dec 12;374(9706):1967-74.
Risk of bleeding with multiple antithrombotics –
following myocardial infarction
12.0% major bleeding per year
![Page 5: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/5.jpg)
Question #1
A 65-year-old woman is admitted for NSTEMI with a markedlyelevated high-sensitivity cardiac troponin level [350 ng/L (ULN<14 ng/L)] and an invasive strategy is planned. She is on vitamin Kantagonist (VKA) for atrial fibrillation with prior stroke and the INRis 2.7. The CHA2DS2-VASc score is 4 and radial access seemsfeasible. How do you manage the timing of angiography?
Early angiography on VKA
Delayed angiographyafter switch
![Page 6: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/6.jpg)
Answer #1
Angiography should be performed on VKA, with no need foradditional anticoagulation at the time of the procedure. Radialaccess is recommended. Interruption of VKA and bridging withparenteral anticoagulation should be avoided, given the increasedrisk of bleeding.
Early angiographyon VKA
Delayed angiographyafter switch
![Page 7: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/7.jpg)
Question #2
A 65-year-old woman is admitted for NSTEMI with a markedlyelevated high-sensitivity cardiac troponin level [350 ng/L (ULN<14 ng/L)] and an invasive strategy is planned. She is on vitamin Kantagonist (VKA) for atrial fibrillation with prior stroke and the INRis 2.7. The CHA2DS2-VASc score is 4 and radial access seemsfeasible. How do you manage anticoagulation therapy?
ParenteralAnticoagulation
No ParenteralAnticoagulation
![Page 8: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/8.jpg)
•Angiography should be performed on VKA, with no need for additional anticoagulation at the time of the procedure.
Anwer #2
ParenteralAnticoagulation
No ParenteralAnticoagulation
![Page 9: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/9.jpg)
Question #3: Would the lack of radial access in this patient change your strategy?
YES NO
![Page 10: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/10.jpg)
If radial access is not feasible, VKA may be discontinued and angiography may be postponed until the INR is 2. If there is
YES NO
Answer #3
![Page 11: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/11.jpg)
Recommendations Class Level Ref.
In centres experienced with radial access, a radial approach isrecommended for coronary angiography and PCI.
I A MATRIX
Recommendations for invasive coronaryangiography and revascularization in NSTE-ACS
The choice of vascular access site depends on operator expertise and local preference, but, due
to the large impact of bleeding complications on clinical outcome in patients with elevated
bleeding risk, the choice may become important. Since the radial approach has been shown to
reduce the risk of bleeding when compared with the femoral approach, this access site should be
preferred in patients at high risk of bleeding provided the operator has sufficient experience with
this technique
2011 NSTEACS GL No formal reco for access site selection
page 3007
2015 NSTEACS GL
![Page 12: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/12.jpg)
Question #4: Would you pretreat this patient with oral P2Y12 inhibitors?
YES NO
![Page 13: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/13.jpg)
Answer #4
YES NO
Pretreatment is not encouraged up until the revascularizationstratety is clear.
![Page 14: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/14.jpg)
Patients on OAC
![Page 15: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/15.jpg)
Question #5: Would you use DES?
YES NO
![Page 16: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/16.jpg)
Question #5: Would you use DES?
YES NO
![Page 17: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/17.jpg)
Drug Eluting Stent
Valgimigli M et al. J Am CollCardiol2015;65: 805–15
![Page 18: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/18.jpg)
Anticoagulation during Stenting on OAC
![Page 19: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/19.jpg)
Leaders Free
Urban Ph et al. NEJM 2015
![Page 20: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/20.jpg)
Leaders Free
Urban Ph et al. NEJM 2015
![Page 21: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/21.jpg)
Question #6: An LAD lesion is eligible for
coronary stenting. For how long triple therapy?
One month Six months
![Page 22: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/22.jpg)
One month Six months
Answer #6
HASBLED is 3
![Page 23: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/23.jpg)
Question #7
She has been on triple therapy (i.e. aspirin, clopidogreland VKA) for 1 month and then on a combination ofaspirin and VKA. At one year, she has been symptom-free since then (no bleeding and no ischemia). Herprimary care physician is asking whether aspirin canbe stopped.
YES NO
![Page 24: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/24.jpg)
•Although this question has never been prospectively addressed, based on expert consensus, aspirin may be stopped because there are no high-risk features for a recurrent coronary event (e.g. three-vessel disease CAD, left main stenting, recurrent ischaemic symptoms).
Answer #7
YES NO
![Page 25: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/25.jpg)
2016 AFIB Guidelines
![Page 26: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/26.jpg)
Beyond one year
"...in very selected patients at high risk of ischaemic events:
prior stent thrombosis on adequate antiplatelet therapy,
stenting in the left main or last remaining patent coronary artery,
multiple stenting in proximal coronary segments,
two stents bifurcation treatment,
or diffuse multivessel disease, especially in diabetic patients.
![Page 27: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/27.jpg)
Antiplatelet Therapy after Stenting on OAC
![Page 28: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/28.jpg)
28
Help to implementGL in daily practice
• 40 cases each• No reference• Link to the dedicatedsections of the GL
European Heart Journaldoi:10.1093/eurheartj/ehv409
European Heart Journaldoi:10.1093/eurheartj/ehv407
European Heart Journaldoi:10.1093/eurheartj/ehv408
![Page 29: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/29.jpg)
Thank you
![Page 30: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/30.jpg)
![Page 31: Antithrombotic therapy in CAD patients with concomitant ......•Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting](https://reader033.fdocuments.us/reader033/viewer/2022060716/607cbfafd6b3f173e71a35a6/html5/thumbnails/31.jpg)
• Roffi M, Patrono C, Collet JP, et al. Task Force for the Management of Acute
Coronary Syndromes in Patients Presenting without Persistent ST-Segment
Elevation of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the
management of acute coronary syndromes in patients presenting without persistent
ST-segment elevation: Eur Heart J. 2015 Aug 29.
• Collet JP, Roffi M, Mueller C, Valgimigli M, Patrono C, Baumgartner H, Gaemperli O,
Zamorano JL. Questions and answers on antithrombotic therapy: a companion document
of the 2015 ESC Guidelines for the ²management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation. Eur Heart J. 2015 Aug 29.
• Mueller C, Patrono C, Valgimigli M, Collet JP, Roffi M. Questions and answers on diagnosis
and risk assessment: a companion document of the 2015 ESC Guidelines for the
management of acute coronary syndromes in patients presenting without persistent ST-
segment elevation. Eur Heart J. 2015 Aug 29.
• Valgimigli M, Patrono C, Collet JP, Mueller C, Roffi M. Questions and answers on coronary
revascularization: a companion document of the 2015 ESC Guidelines for the management
of acute coronary syndromes in patients presenting without persistent ST-segment
elevation. Eur Heart J. 2015 Aug 29.
Main references
31